Astria Therapeutics Inc. (ATXS), a biopharmaceutical company developing therapies for allergic and immunologic diseases, has a near-term catalyst to watch involving its drug candidate STAR-0310.
STAR-0310 is a monoclonal antibody OX40 antagonist that is in development for the potential treatment of atopic dermatitis (AD). OX40 inhibition is a clinically validated mechanism for the treatment of AD.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com